- Alnylam’s adjusted earnings per share (EPS) for the second quarter were higher than expected at 32 cents, compared to last year’s 56 cents and an expected loss of 3.6 cents.
- The company reported a loss per share of 51 cents, against last year’s loss of 13 cents, outperforming the anticipated loss of 57 cents per share.
- Total revenue was $773.7 million, up 17% from the previous year and surpassed the forecast of $667.3 million.
- Net product revenues showed significant growth, reaching $672.2 million, a 64% increase year-over-year, exceeding the estimate of $529.2 million.
- Collaboration revenue decreased by 73% to $61.5 million, falling short of the expected $88.8 million.
- Operating expenses rose to $789.9 million, a 29% increase from the prior year, above the estimate of $709.2 million.
- Cash and cash equivalents were at $1.11 billion, marking a 15% increase year-over-year but below the expected $1.22 billion.
- Adjusted research and development expenses totaled $274.1 million, slightly above the estimated $266.7 million.
- Alnylam raised its 2025 guidance for TTR franchise net revenues to a range of $2,175 million to $2,275 million.
- Total net product revenues for 2025 are projected to rise to between $2,650 million and $2,800 million, representing a 27% increase at the midpoint.
- Market analysts have rated the company’s stock with 25 buy ratings, 7 hold ratings, and 2 sell ratings.
Alnylam Pharmaceuticals on Smartkarma
Analyst coverage on Alnylam Pharmaceuticals on Smartkarma reveals positive sentiments from Baptista Research analysts. In a report titled “Alnylam Pharmaceuticals: Why Its TTR Franchise Expansion Can Be A Game Changer!”, the analysts highlight the company’s recent first-quarter 2025 earnings, showcasing a 28% year-over-year growth in net product revenues to $469 million. This neutral analysis provides insights into the company’s financial performance, strategic initiatives, and future outlook.
Moreover, in another report titled “Alnylam Pharmaceuticals: The Groundbreaking ATTR Amyloidosis Expansion That’s Turning Heads!”, Baptista Research further praises Alnylam Pharmaceuticals for achieving strong results in the fourth quarter and full year 2024. With net product revenues exceeding $1.6 billion, representing a remarkable 33% growth from the previous year, the company’s performance is driven by the increasing adoption of their therapeutics for hereditary transthyretin mediated (hATTR) amyloidosis and other rare diseases. These reports showcase optimism towards Alnylam Pharmaceuticals‘ growth prospects and innovative advancements in genetic medicine.
A look at Alnylam Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alnylam Pharmaceuticals, an early-stage therapeutics company, is positioned for solid growth and strong momentum based on the Smartkarma Smart Scores. With a high Growth score of 4 and a top-notch Momentum score of 5, the company shows promising potential for significant expansion in the long term.
Although Alnylam Pharmaceuticals scores lower on Value and Dividend factors, with scores of 2 and 1 respectively, its focus on developing cutting-edge technology to target disease-causing genes demonstrates resilience in the face of challenges. This could pave the way for sustained success and innovation in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
